ESSA Pharma Inc. — Director's Dealing 2021

Jan 11, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ESSA Pharma Inc. (EPIX)
CIK: 0001633932
Period of Report: 2020-12-03

Reporting Person: BERGER FRANKLIN M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-03	Common Shares	M	1716	$4.00	Acquired	859753	Direct
2020-12-03	Common Shares	M	6534	$4.00	Acquired	866287	Direct
2020-12-03	Common Shares	M	2184	$3.81	Acquired	868471	Direct
2020-12-03	Common Shares	M	25000	$3.23	Acquired	893471	Direct
2020-12-03	Common Shares	M	6773	$4.67	Acquired	900244	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-03	Stock Option (Right to Buy)	$4.00	M	1716	Disposed	2025-03-05	Common Shares (1716)	Direct
2020-12-03	Stock Option (Right to Buy)	$4.00	M	6534	Disposed	2028-02-21	Common Shares (6534)	Direct
2020-12-03	Stock Option (Right to Buy)	$3.81	M	2184	Disposed	2029-02-08	Common Shares (2184)	Direct
2020-12-03	Stock Option (Right to Buy)	$3.23	M	25000	Disposed	2029-10-04	Common Shares (25000)	Direct
2020-12-03	Stock Option (Right to Buy)	$4.67	M	6773	Disposed	2029-10-30	Common Shares (6773)	Direct
2020-12-11	Stock Option (Right to Buy)	$7.00	A	16500	Acquired	2030-12-11	Common Shares (16500)	Direct

Footnotes

F1: 25% of the options vest after 12 months from the date of grant, and the remaining 75% vest in 36 equal installments with the first installment vesting at the end of the 13th month and subsequent installments vesting on every one month anniversary thereafter.